How Is Becton, Dickinson and Company's Stock Performance Compared to Other Medical Devices Stocks?

Becton, Dickinson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Valued at $51.7 billion by market cap, the company offers solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, and promote infection prevention.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and BDX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical instruments & supplies industry. BDX excels in medical technology with a strong global brand, extensive distribution network, and broad product portfolio. Its commitment to innovation, significant R&D investments, and strategic acquisitions drive growth, while its robust manufacturing and supply chain ensure reliable product delivery, positioning BDX as a leader in the healthcare industry.

Despite its notable strength, BDX slipped 2.8% from its 52-week high of $193.07, achieved on Aug. 24. Over the past three months, BDX stock gained 28.9%, outperforming the iShares U.S. Medical Devices ETF’s (IHI) 11.1% gains during the same time frame.

Shares of BDX rose 23% on a YTD basis and climbed 25.9% over the past 52 weeks, notably outperforming IHI’s YTD losses of 13.3% and 12% over the last year.

To confirm the bullish trend, BDX has been trading above its 50-day and 200-day moving averages since late June, with slight fluctuations. 

BDX stock rallied as robust demand for its high-margin GLP-1 drug delivery systems and the successful relaunch of its Alaris infusion pumps drove strong U.S. organic growth. This operational momentum, complemented by aggressive cost-efficiency initiatives, strategic portfolio moves to streamline operations, and reduced earnings exposure to market drags in China, allowed the company to consistently beat earnings estimates and raise forward guidance, decisively restoring institutional investor confidence.

On Aug. 6, BDX shares closed up by 3.8% after reporting its Q3 results. Its adjusted EPS of $3.23 beat Wall Street expectations of $3.14. The company’s revenue was $5 billion, exceeding Wall Street forecasts of $4.9 billion. BDX expects full-year adjusted EPS in the range of $12.62 to $12.72.

BDX’s rival, Solventum Corporation (SOLV) shares have taken the lead over the stock, with a 29.5% gain over the past 52 weeks, but lagged behind the stock with a 16.7% uptick on a YTD basis. 

Wall Street analysts are reasonably bullish on BDX’s prospects. The stock has a consensus “Moderate Buy” rating from the 16 analysts covering it, and the mean price target of $190.47 suggests a potential upside of 1.5% from current price levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.